Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06296264
Recruiting Not applicable

Ultra-portable Ultrasound vs. Standard Ultrasound to Help Place a Peripheral Catheter in Patients at Risk of Difficult Puncture

NCT06296264 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Saint Joseph Saint Luc de Lyon
Phase
Not applicable
Started
2024-08-27
Last updated
2024-10-24

Condition(s) studied

IV Line Placement With Ultrasound

Investigational drug(s) / intervention(s)

Standard ultrasoundUltra-portable ultrasound

Standard ultrasound: Placement of IV line using standard ultrasound.

Ultra-portable ultrasound: Placement of IV line using ultra-portable ultrasound.

Study summary

The placement of an intravenous (IV) line is a common procedure when treating adult patients in critical care, in the emergency room or in the operating room. This simple and minimally invasive procedure can sometimes be made difficult depending on the patient's morphology or their clinical condition. The procedure then becomes time-consuming, anxiety-provoking, painful and its success is uncertain.

The placement of intravenous (IV) lines under ultrasound by nurses is a rapidly developing alternative in intensive care, emergencies and the operating room.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patient aged at least 18 years old 2. Patient with an A-DIVA (Adult Difficult Intravenous Access) score \> 1 3. Supported by a nurse trained in all the techniques used in the protocol 4. Patient having given free, informed and oral consent - Exclusion Criteria: 1. Patient who has already been included in the study 2. Patient whose inclusion in the study would lead to a delay in treatment 3. Adult patient protected by law 4. Pregnant woman 5. Patient not benefiting from French Social Security system -

Primary outcome measure(s)

  • Intravenous (IV) line placement time — Day 0
    Time in minutes between tourniquet placement and dressing application after placement.

Trial sites (1)

FacilityCityRegionStatus
Saint Joseph Saint Luc Hospital Lyon Auvergne-Rhône-Alpes Recruiting

More Centre Hospitalier Saint Joseph Saint Luc de Lyon trials in France

Bedside Observation by Clinical Ultrasound for Stomach Expansion Recruiting
Video Tutorial and Oral Explanation Vs Oral Explanation Alone in Colonoscopy Preparation Recruiting
Titration of Positive End-expiratory Pressure: Comparison Between Manual Thoracic or Abdominal Compression and Electrical Impedance Tomography Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06296264 on ClinicalTrials.gov ↗ ← All trials in France